Experimental study on antileukemia effects of anti-CD3/interleukin-2 costimulated killer cells and interleukin-2 liposomes plus kappa-selenocarrageenan

Hulai Wei,Zhengping Jia,Huaishun Zhao

1998-01-01

Abstract:Objective To study the antileukemia and immunomodulating effect of T-activated killer (T-AK) cells induced by anti-CD3 antibody and interleukin-2 costimulation and liposomal interleukin-2 (L-IL-2) plus kappa-selenocarrageenan (KSC) on L1210 leukemia mice. Methods T-AK cells were induced in splenocytes from normal DBA/2 mice with anti-CD3 monoclonal antibody and rIL-2. The murine L1210 leukemia model was established by ip injection of L1210 cells in DBA/2 mice, and according to the experimental protocol the L1210-bearing mice were administrated with adoptive transfer of T-AK cells plus L-IL-2 (T-AK/L-IL-2) and KSC. The cellular immune functions and the life spans of the mice were determined. Results After tumor inoculation the cellular immune functions of L1210-bearing mice decreased significantly, and their life spans were 16. 43 ± 1. 92 days. Adoptively transfected T-AK cells (5 × 106/mice) and L-IL-2 (104U/kg) could partly reverse the decrease tendency of lymphocytic proliferation activity, NK cytotoxicity and IL-2 producing ability of the leukemia mice, and the survival time of the tumor-bearing mice was prolonged to 24. 78 ± 3. 94 days (P<0. 01), and 14. 3% of the leukemic mice were cured. KSC (40mg/kg) enhanced markedly the antileukemic and immunopotentiating activities of T-AK/L-IL-2 therapy. The rate of life prolongation was 36%, and the cure rate of the leukemia mice was doubled. Conclusions KSC possess the activities of biological response modifier (BRM). The biotherapeutic program of T-AK cells and IL-2 liposomes with adjuvant of BRM-like immunocompetent potentiator KSC has great antitumor and immuno-potentiating actions on murine L1210-leukemia.